Juluca (Dolutegravir Sodium, Rilpivirine Hydrochloride)

Dolutegravir sodium belongs to the integrase strand transfer inhibitor class. It binds to the active site of the HIV integrase enzyme, preventing the insertion of viral DNA into the host cell genome, a critical step required for viral replication. By blocking integration, dolutegravir stops the virus from establishing a permanent infection in the cell.

Rilpivirine hydrochloride is a non‑nucleoside reverse transcriptase inhibitor. It attaches to a specific site on the HIV reverse transcriptase enzyme, causing a conformational change that inhibits the enzyme’s ability to convert viral RNA into DNA. This interruption halts the early stage of viral replication, complementing the action of dolutegravir.

The prescribed dose of Juluca is determined by the treating clinician based on the patient’s medical history, resistance profile, and concomitant medications. The product is supplied as a single film‑coated tablet containing 50 mg dolutegravir sodium and 25 mg rilpivirine hydrochloride, taken orally once daily with food, unless the prescriber advises otherwise.

Safety data for Juluca in pregnancy and lactation are limited. The medication should only be used if the potential benefits to the mother outweigh the possible risks to the fetus or infant. Healthcare providers typically assess individual risk factors and may consider alternative regimens when safer options are available.

To request Juluca, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Juluca combines an integrase inhibitor with a non‑nucleoside reverse transcriptase inhibitor, whereas many other single‑tablet regimens pair an integrase inhibitor with two nucleoside reverse transcriptase inhibitors. This difference can reduce pill burden and may be preferred for patients who have contraindications to nucleoside agents, but efficacy and safety should be evaluated individually.

Juluca tablets should be stored at ambient temperature, below 25 °C (77 °F). Keep the medication in its original blister pack or container, protect it from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Juluca is taken orally as a single film‑coated tablet once daily, preferably with a meal to enhance rilpivirine absorption. Swallow the tablet whole with water; do not crush, chew, or split it unless specifically instructed by a healthcare professional.

Juluca is contraindicated in patients with known hypersensitivity to either dolutegravir sodium, rilpivirine hydrochloride, or any of the tablet’s excipients. It should also be avoided in individuals with documented resistance to integrase inhibitors or NNRTIs, and caution is advised for patients with severe hepatic impairment or those taking interacting medications listed as major interactions.